Eve Thomas, Author at Clinical Trials Arena

Corcept’s relacorilant GRADIENT trial misses primary endpoint

Eve Thomas — Fri, 01 Nov 2024 11:17:17 +0000

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's syndrome patients.

The post Corcept’s relacorilant GRADIENT trial misses primary endpoint appeared first on Clinical Trials Arena.

Reeves’ 2024 budget promises life sciences investment

Eve Thomas — Thu, 31 Oct 2024 14:48:49 +0000

Reeves' budget promised investment for innovation and R&D with a view to "harnessing the full potential of the UK’s science base”.

The post Reeves’ 2024 budget promises life sciences investment appeared first on Clinical Trials Arena.

mRNA licensing agreements surge 800% amid GSK lawsuits

Eve Thomas — Fri, 18 Oct 2024 19:14:09 +0000

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are facing lawsuits.

The post mRNA licensing agreements surge 800% amid GSK lawsuits appeared first on Clinical Trials Arena.

MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study

Eve Thomas — Wed, 16 Oct 2024 19:43:22 +0000

The AAV-GAD bridging study met the primary endpoint of safety and tolerability and showed early promise in Parkinson’s patients.

The post MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study appeared first on Clinical Trials Arena.

As mpox spreads, ‘national governments have a moral responsibility to help’

Eve Thomas — Thu, 05 Sep 2024 16:38:27 +0000

Representatives of the WHO and the IFRC called for international cooperation to tackle the current mpox outbreak.

The post As mpox spreads, ‘national governments have a moral responsibility to help’ appeared first on Clinical Trials Arena.

What is mpox and how big of a threat is it?

Eve Thomas — Tue, 27 Aug 2024 11:01:46 +0000

Declared a PHEIC by the WHO, an mpox outbreak in the DRC is posing a threat to human health.

The post What is mpox and how big of a threat is it? appeared first on Clinical Trials Arena.

Anti-obesity drugs will be 2024’s defining trend

Eve Thomas — Wed, 12 Jun 2024 12:00:52 +0000

GlobalData’s newest update notes the impact of the growing anti-obesity market, apersonalised medicines, real-world evidence, and cell and gene therapies.

The post Anti-obesity drugs will be 2024’s defining trend appeared first on Clinical Trials Arena.

Psilocybin effective in treating depression

Eve Thomas — Tue, 07 May 2024 16:27:13 +0000

A new study has further supported psilocybin's potential to treat depression, which impacts around 300 million people globally.

The post Psilocybin effective in treating depression appeared first on Clinical Trials Arena.

Psychedelic treatments for mental health: Is there substance behind the hype?

Eve Thomas — Wed, 21 Feb 2024 15:39:37 +0000

The success of recent trials treating mental health problems with psychedelic therapies has driven a rapid rise in investment in the area.

The post Psychedelic treatments for mental health: Is there substance behind the hype? appeared first on Clinical Trials Arena.

Remote Patient Monitoring market will reach $760m by 2030

Eve Thomas — Fri, 15 Sep 2023 15:48:43 +0000

A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.

The post Remote Patient Monitoring market will reach $760m by 2030 appeared first on Clinical Trials Arena.